ArticleFrontiers in surgery2025
Clinical features and oncologic outcomes of primary retroperitoneal ganglioneuroma: a retrospective cohort study of 51 patients from a high-volume sarcoma center.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retroperitoneal ganglioneuroma (RGN) is a rare, benign tumor derived from neural crest cells of the sympathetic nervous system. Due to its rarity and complex management, clinical understanding remains limited. This study aimed to analyze the clinical features and surgical outcomes of RGN. Methods: A retrospective analysis was performed utilizing the retroperitoneal tumor database of Peking University International Hospital. Patients who underwent surgical resection for pathologically confirmed primary RGN between January 2015 and August 2024 were included. Systematic postoperative follow-up was conducted to assess outcomes. Results: Fifty-one consecutive patients (18 males, 33 females; median age 28 years, range 12-73) with newly diagnosed RGN were enrolled. Clinical presentations were heterogeneous: 29 cases (56.9%) were incidental findings on physical examination, 16 (31.4%) reported abdominal discomfort, 3 (5.9%) had lumbago, and single cases presented with hematuria, chest tightness, or lower limb pain. R0/R1 resection was achieved in 45 patients (88.2%). Postoperative complications occurred in 11 patients (21.6%), including gastroparesis ( Conclusions: Retroperitoneal ganglioneuroma (RGN) is a rare benign tumor that frequently presents with nonspecific symptoms. While surgical resection remains the cornerstone of management, it is best undertaken at specialized, high-volume sarcoma centers to mitigate operative risks. When complete excision is precluded by critical vascular involvement, subtotal resection represents a judicious alternative. For selected patients with small, asymptomatic tumors-particularly those with elevated surgical risk-active surveillance is a reasonable option. Despite a generally favorable prognosis, long-term follow-up is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.